Edgewise Therapeutics, Inc. (EWTX)
| Market Cap | 3.90B +150.9% |
| Revenue (ttm) | n/a |
| Net Income | -176.01M |
| EPS | -1.66 |
| Shares Out | 107.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 890,851 |
| Open | 38.03 |
| Previous Close | 37.25 |
| Day's Range | 36.06 - 38.03 |
| 52-Week Range | 12.15 - 40.77 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 49.13 (+35.48%) |
| Earnings Date | May 7, 2026 |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price target is $49.13, which is an increase of 35.48% from the latest price.
News
Edgewise Therapeutics price target lowered to $48 from $50 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $48 from $50 and keeps an Outperform rating on the shares. The company’s sale of…
Edgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Edgewise Therapeutics (EWTX) to $45 from $42 and keeps a Buy rating on the shares. The sale of sevasemten for up to…
Edgewise Therapeutics price target raised to $66 from $52 at Raymond James
Raymond James analyst Martin Auster raised the firm’s price target on Edgewise Therapeutics (EWTX) to $66 from $52 and keeps a Strong Buy rating on the shares after Edgewise announced…
Edgewise Therapeutics deal ‘looks really strong,’ says Stifel
After Edgewise Therapeutics (EWTX) announced that it has entered into a definitive agreement under which Servier will acquire sevasemten and Edgewise’s muscular dystrophy business for $1.55B in upfron...
Edgewise Therapeutics rises 17.5%
Edgewise Therapeutics (EWTX) is up 17.5%, or $5.99 to $40.15.
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
08:31 EDT Servier to acquire Edgewise Therapeutics (EWTX)’ muscular dystrophy business for $2.65B
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
Servier, an independent international pharmaceutical group governed by a foundation, announced that it has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics...
Edgewise Therapeutics confirms sale of sevasemten for up to $2.65B
Edgewise Therapeutics (EWTX) announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sev...
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France's Servier for up to $2.65 billion.
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovascular C...
Edgewise Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
EDG-7500 offers a differentiated mechanism with robust efficacy and safety in HCM, avoiding ejection fraction reduction and enabling easier real-world use. Upcoming data and regulatory feedback may further support its broad adoption, while the Grand Canyon study aims to confirm functional benefits in dystrophies.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at th...
Edgewise Therapeutics Quarterly report: Q1 2026
Edgewise Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Edgewise Therapeutics Earnings release: Q1 2026
Edgewise Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Edgewise Therapeutics reports Q1 EPS (46c), consensus (49c)
Cash, cash equivalents and marketable securities were approximately $499.6M as of March 31.”For the first time with an investigational agent, we have generated long-term data showing that people with ...
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up – – CIRRUS-HCM 12-week data of EDG-...
Edgewise Therapeutics price target raised to $52 from $46 at Truist
Truist raised the firm’s price target on Edgewise Therapeutics (EWTX) to $52 from $46 and keeps a Buy rating on the shares. The firm is citing the company’s ACACIA data…
Edgewise Therapeutics rises 18.1%
Edgewise Therapeutics (EWTX) is up 18.1%, or $5.70 to $37.15.
Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James
Cytokinetics (CYTK) reported statistically positive Phase 3 ACACIA results for aficamten in non-obstructive hypertrophic cardiomyopathy, an outcome that bodes well for Edgewise Therapeutics (EWTX), as...
Edgewise Therapeutics rises 23.3%
Edgewise Therapeutics (EWTX) is up 23.3%, or $7.33 to $38.78.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics ...
Edgewise Therapeutics Proxy statement: Proxy filing
Edgewise Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Edgewise Therapeutics Proxy statement: Proxy filing
Edgewise Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
JPMorgan ups Edgewise target, adds to Analyst Focus List
JPMorgan raised the firm’s price target on Edgewise Therapeutics (EWTX) to $45 from $34 and keeps an Overweight rating on the shares. JPMorgan also added Edgewise to its Analyst Focus…
Edgewise Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Key cardiovascular and neuromuscular programs are advancing, with 7500 showing a favorable safety profile and plans for Phase III in HCM by year-end. Becker muscular dystrophy data indicate disease stabilization, and new HFpEF candidates are progressing.